Skip to main content
Moleculin Biotech, Inc. logo

Moleculin Biotech, Inc. — Investor Relations & Filings

Ticker · MBRX ISIN · US60855D2009 LEI · 549300IB1TLJZCHEO353 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2017-08-19 Director's Dealing
Country US United States of America
Listing US MBRX

About Moleculin Biotech, Inc.

https://moleculin.com/

Moleculin Biotech, Inc. is a late-stage clinical pharmaceutical company focused on developing a portfolio of therapeutic candidates for highly resistant cancers and viruses. The company's lead drug candidate is Annamycin, a next-generation liposomal anthracycline designed to be non-cardiotoxic and to circumvent multidrug resistance. Annamycin is being advanced in a pivotal Phase 3 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company's development pipeline also includes other drug candidates targeting hard-to-treat tumors.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2017-08-19 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Shelf Registration Statement on Form S-3. It is a regulatory communication related to securities registration and does not contain financial statements, management discussion, or detailed financial data. The document is short (1909 characters) and is a formal request rather than a report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2017-08-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 14, 2017, reporting the issuance of a press release announcing financial results for the quarter ended June 30, 2017. The text states that the press release is attached as Exhibit 99.1 and incorporated by reference. The document itself does not contain the financial results or detailed financial statements but rather announces the release of such information. The length of the document is 3638 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release of financial results) rather than the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement and does not contain substantive financial data or the full earnings release text.
2017-08-14 English
Regulatory Filings 2017
Regulatory Filings Classification · 95% confidence The document is a correspondence letter addressed to the SEC regarding comments on a Registration Statement on Form S-3 filed by Moleculin Biotech, Inc. It discusses revisions to the prospectus cover page and eligibility to use Form S-3. The content is a response to regulatory comments and does not contain financial statements, earnings data, or detailed report content. The document length is short (2920 characters) and it is clearly a regulatory correspondence related to a filing, not the filing itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such correspondence and comment responses to the SEC.
2017-08-11 English
S-3/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-3/A registration statement amendment filed with the SEC, which is used for registering securities for sale to the public. It includes a prospectus for a shelf registration allowing the company to issue up to $75 million in various securities such as common stock, preferred stock, debt securities, warrants, or units. The document contains detailed information about the securities offering, risk factors, use of proceeds, and legal matters. It is not a financial report, earnings release, management discussion, or any other report type but rather a capital raising and securities registration filing. Therefore, it fits the category of Capital/Financing Update (CAP).
2017-08-11 English
10-Q
Interim / Quarterly Report Q2 2017
2017-08-11 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.